

# Suriname

Population 2015

<1 million

| Estimates of TB burden*, 2015 | Number (thousands)  | Rate (per 100 000 population) |
|-------------------------------|---------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 0.014 (0.014–0.015) | 2.6 (2.5–2.8)                 |
| Mortality (HIV+TB only)       | 0.011 (<0.01–0.024) | 2 (0.54–4.4)                  |
| Incidence (includes HIV+TB)   | 0.18 (0.14–0.23)    | 33 (26–42)                    |
| Incidence (HIV+TB only)       | 0.055 (0.042–0.07)  | 10 (7.8–13)                   |
| Incidence (MDR/RR-TB)**       | 0.024 (0.011–0.037) | 4.4 (2–6.8)                   |

## Estimated TB incidence by age and sex (thousands)\*, 2015

|         | 0-14 years          | > 14 years          | Total               |
|---------|---------------------|---------------------|---------------------|
| Females | 0.01 (<0.01–0.014)  | 0.053 (0.027–0.079) | 0.063 (0.032–0.093) |
| Males   | <0.01 (<0.01–0.011) | 0.11 (0.082–0.14)   | 0.12 (0.087–0.15)   |
| Total   | 0.018 (0.012–0.024) | 0.16 (0.14–0.19)    | 0.18 (0.14–0.23)    |

## TB case notifications, 2015

|  |     |
|--|-----|
| Total cases notified                                   | 150 |
| Total new and relapse                                  | 144 |
| - % tested with rapid diagnostics at time of diagnosis | 78% |
| - % with known HIV status                              | 97% |
| - % pulmonary  | 83% |
| - % bacteriologically confirmed among pulmonary        | 77% |

## Universal health coverage and social protection

|  |                  |
|--|------------------|
| TB treatment coverage (notified/estimated incidence), 2015             | 80% (64–100)     |
| TB patients facing catastrophic total costs                            |                  |
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 | 0.14 (0.08–0.22) |

## TB/HIV care in new and relapse TB patients, 2015

|   | Number | (%) |
|---|--------|-----|
| Patients with known HIV-status who are HIV-positive | 42     | 30% |
| - on antiretroviral therapy                         | 26     | 62% |

| Drug-resistant TB care, 2015                                | New cases     | Previously treated cases | Total number*** |
|---|---------------|--------------------------|-----------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases |               |                          | 14 (5–23)       |
| Estimated % of TB cases with MDR/RR-TB                      | 9.9% (4.1–19) | 25% (0.63–81)            |                 |
| % notified tested for rifampicin resistance                 | 77%           | 40%                      | 112             |
| MDR/RR-TB cases tested for resistance to second-line drugs  |               |                          | 0               |
| Laboratory-confirmed cases                                  |               | MDR/RR-TB: 8, XDR-TB: 0  |                 |
| Patients started on treatment ****                          |               | MDR/RR-TB: 0, XDR-TB: 0  |                 |

| Treatment success rate and cohort size                          | Success | Cohort |
|---|---------|--------|
| New and relapse cases registered in 2014                        | 77%     | 146    |
| Previously treated cases, excluding relapse, registered in 2014 | 33%     | 12     |
| HIV-positive TB cases, all types, registered in 2014            | 68%     | 37     |
| MDR/RR-TB cases started on second-line treatment in 2013        |         | 0      |
| XDR-TB cases started on second-line treatment in 2013           |         | 0      |

## TB preventive treatment, 2015

|   |  |
|---|--|
| % of HIV-positive people (newly enrolled in care) on preventive treatment                                   |  |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment |  |

## TB financing, 2016

|  |     |
|--|-----|
| National TB budget (US\$ millions)                           | 1.6 |
| Funding source: 57% domestic, 35% international, 8% unfunded |     |

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2015



## Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

## Total budget (US\$ millions)

